Quality analysis of salmon calcitonin in a polymeric bioadhesive pharmaceutical formulation: Sample preparation optimization by DOE

Journal of Pharmaceutical and Biomedical Analysis

Volumn 53, Issue 4, 2010, Pages 939-945

  D'Hondt, Matthias ^a   Van Dorpe, Sylvia ^a   Mehuys, Els ^a   Deforce, Dieter ^a   De Spiegeleer, Bart ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Calcitonin; Degradation; Polymer excipient interaction; Quality by design (QbD DOE); Stability indicating assay

Indexed keywords

ACETONITRILE; AMINO ACID; CALCITONIN; EXCIPIENT; FORMIC ACID; POLYMER; TRIFLUOROACETIC ACID;

ARTICLE; DEGRADATION; DRUG FORMULATION; DRUG ISOLATION; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ION TRAP MASS SPECTROMETRY; MASS SPECTROMETRY; POLYMERIZATION; PRIORITY JOURNAL; SALMON; ULTRAVIOLET SPECTROSCOPY; VALIDATION PROCESS;

AMINO ACID SEQUENCE; CALCITONIN; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; MOLECULAR SEQUENCE DATA; POLYMERS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 77955580690     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.06.028     Document Type: Article

References (31)

1. Copp D.H., Cheney B. Calcitonin-hormone from parathyroid which lowers calcium-level of blood. Nature 1962, 193:381-382.
2. Copp D.H., Davidson A.G., Henze K.G., Cheney B.A., Cameron E.C. Evidence for calcitonin-a new hormone from parathyroid that lowers blood calcium. Endocrinology 1962, 70:638-649.
3. Wimalawansa S.J. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily, Crit. Rev. Neurobiol. 1997, 11:167-239.
4. Roodman G.D. Cell biology of the osteoclast. Exp. Hematol. 1999, 27:1229-1241.
5. Silvestro L., Savu S.R. High-performance liquid chromatography/tandem mass spectrometry identification of salmon calcitonin degradation products in aqueous solution preparations. Rapid Commun. Mass Spectrom. 1996, 10:151-156.
6. Azria M., Copp D.H., Zanelli J.M. 25 years of salmon-calcitonin-from synthesis to therapeutic use. Calcif. Tissue Int. 1995, 57:405-408.
7. Munoz-Torres M., Alonso G., Raya M.P. Calcitonin therapy in osteoporosis. Treat. Endocrinol. 2004, 3:117-132.
8. European Pharmacopoeia 6.0 2007, European Directorate for the Quality of Medicines & Healthcare, Strassbourg, France, pp. 1372-1375.
9. United States Pharmacopeia 2009, United States Pharmacopeia Convention, Rockville, MD, pp. 1747-1751.
10. Gruber H.E., Ivey J.L., Baylink D.J., Mathews M., Nelp W.B., Sisom K., Chesnut C.H. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984, 33:295-303.
11. Basan H., Gümüşderelioĝlu M., Tevfik Orbey M. Release characteristics of salmon calcitonin from dextran hydrogels for colon-specific delivery. Eur. J. Pharm. Biopharm. 2007, 65:39-46.
12. Torres-Lugo M., Peppas N.A. Transmucosal delivery systems for calcitonin: a review. Biomaterials 2000, 21:1191-1196.
13. Cui Z., Mumper R.J. Bucal transmucosal delivery of calcitonin in rabbits using thin-film composites. Pharm. Res. 2002, 19:1901-1906.
14. Yuon Y.S., Kwon M.J., Na D.H., Chae S.Y., Lee S., Lee K.C. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection. J. Controlled Release 2008, 125:68-75.
15. Buclin T., Cosma Rochat M., Burckhardt P., Azria M., Attinger M. Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healty volunteers. J. Bone Miner. Res. 2002, 17:1478-1485.
16. Coucke D., Schotsaert M., Libert C., Pringels E., Vervaet C., Foreman P., Saelens X., Remon J.P. Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine. Vaccine 2009, 27:1279-1286.
17. Coucke D., Vervaet C., Foreman P., Adriaensens P., Carleer R., Remon J.P. Effect on the nasal bioavailability of co-processing drug and bioadhesive carrier via spray-drying. Int. J. Pharm. 2009, 379:67-71.
18. Lee K.C., Yoon J.Y., Woo B.H., Kim C.-K., DeLuca P.P. Post-column fluorescence HPLC for salmon calcitonin formulations. Int. J. Pharm. 1995, 114:215-220.
19. Deftos L.J. Two-site immunoradiometric assay of intact salmon calcitonin. Clin. Chem. 1992, 38:2284-2286.
20. Rong H., Deftos L.J., Ji H., Bucht E. Two-site immunofluorometric assay of intact salmon calcitonin with improved sensitivity. Clin. Chem. 1997, 43:71-75.
21. Windisch V., DeLuccia F., Duhau L., Herman F., Mencel J.J., Tang S.-Y., Vuilhorgne M. Degradation pathways of salmon calcitonin in aqueous solution. J. Pharm. Sci. 1997, 86:359-364.
22. Lee K.C., Lee Y.J., Song H.M., Chun C.J., DeLuca P.P. Degradation of synthetic salmon calcitonin in aqueous solution. Pharm. Res. 1992, 11:1521-1523.
23. Song K.-H., An H.-M., Kim H.-J., Ahn S.-H., Chung S.-J., Shim C.-K. Simple liquid chromatography-electrospray ionization mass spectrometry method for the routine determination of salmon calcitonin in serum. J. Chromatogr. B 2002, 775:247-255.
24. Lee H.S., Choi S.J., Lee H.M., Jeong C.K., Kim S.B., Lee J.T., Yoo S.D., DeLuca P.P., Lee K.C. Determination of salmon calcitonin in formulations by high-performance liquid chromatography with electrochemical detection. Chromatographia 1999, 50:701-704.
25. Cook T.J., Shenoy S.S. Stability of calcitonin salmon in nasal spray at elevated temperatures. Am. J. Health-Syst. Pharm. 2002, 59:713-715.
26. ® 974P used as carriers for nasal drug delivery. Int. J. Pharm. 2009, 378:45-50.
27. Eriksson L., Johansson E., Kettaneh-Wold N., Wikström C., Wold S. Design of Experiments principles and application, third edition 2008, Umetrics Academy, Stockholm.
28. Vergote V., Burvenich C., Van de Wiele C., De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J. Pept. Sci. 2009, 15:697-710.
29. Walker G.F., Ledger R., Tucker I.G. Carbomer inhibits tryptic proteolysis of luteinizing hormone-releasing hormone and N-alpha-benzoyl-L-arginine ethyl ester by binding the enzyme. Pharm. Res. 1999, 16:1074-1080.
30. Lucke A., Kiermaier J., Göpferich A. Peptide acylation by poly(alpha-hydroxy esters). Pharm. Res. 2002, 19:175-181.
31. ® 974P to deliver nonelectrolytes and salts of weakly basic drugs. Int. J. Pharm. 2006, 321:62-71.